4D Molecular Therapeutics, Inc.(FDMT)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

4D Molecular Therapeutics, Inc. (FDMT) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores FDMT at 34.5/100 on a 32-signal composite quality model, placing it at rank #2,344 of 2,961 stocks — the bottom half of the AI-ranked universe. FDMT scores in the top quartile across revenue growth (99.3), institutional flow (97.4). Areas of concern include free cash flow (5.0) and profitability (5.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 7.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), 4D Molecular Therapeutics, Inc. reports quarterly revenue of $3.8M, net income of $-72.9M. Top institutional holders of FDMT by reported 13-F value include Jupiter Topco, RA CAPITAL MANAGEMENT, L.P., BlackRock, based on the most recent SEC filings. FDMT trades on the Nasdaq exchange and files with the SEC under CIK 1650648. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate FDMT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for 4D Molecular Therapeutics, Inc. directly from SEC EDGAR.